Press Room


    Press Release - June 17, 2002

    UK's Largest Healthcare Retailer to Distribute Pheromone's Fertility Monitor

    Pheromone Sciences Signs First Commercialization Agreement

    Toronto, Ontario (June 17, 2002) -- Pheromone Sciences Corp. (TSX Venture Exchange:PHS), a Toronto- based biotech R & D company with proprietary technology in the field of non-invasive fertility and ovulation detection and Tri-Vision International Ltd./Lt�©e (TSX:TVL), a consumer electronics and marketing company with special retail relationships across the UK are pleased to announce the signing of a Letter of Intent (LOI) for the distribution of Pheromone's PSC Fertility Monitor(tm) in the United Kingdom. The LOI is expected to be followed by a definitive Distribution Agreement. The distribution agreement is to provide for the sale of the PSC Fertility Monitor exclusively in Boots Company PLC across the United Kingdom over a three-year period.

    Boots is the UK's largest retailer of health products in the United Kingdom with over 1,400 retail outlets and a strong Internet based pharmacy network. Under the proposed distribution agreement Boots would be committed to selling a significant number of units of the product during each year. The product is expected to be available in Boots outlets before year-end.

    The PSC Fertility Monitor is a fertility cycle monitoring device for the consumer and professional medical market. The PSC Fertility Monitor looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning. The PSC Fertility Monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio-sensing and computer technologies. These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

    As demonstrated in the recent US trial, the PSC Fertility Monitor detected more days of the conception window (the days when sexual intercourse can lead to a pregnancy) than the LH test strip product or the basal body temperature method. This determination, coupled with the published literature on the chances of conception during this window strongly suggests that women who use the PSC Fertility Monitor as a means of identifying their fertile window to time intercourse, can expect a substantially higher probability of conception or a substantially shorter time to pregnancy than if they relied solely on home based LH test kits as a means to time intercourse.

    "The signing of this "LOI" represents a significant step in the execution of our commercialization strategy, stated Christopher Neuman", President and CEO of Pheromone. "Much effort has been put into the development of our Fertility Monitor technology and this solid expression of interest from one of the world's leading health care retailing organizations is a validation of our efforts to bring this technology to couples around the world."

    This business agreement is the first for Tri- Vision's newly established Tri-Vision Technologies International Inc. subsidiary, which was created for the development and marketing of innovative technologies.

    "While this is our first endeavor in delivering new technologies for other companies, our core business has been operating internationally for years and we continue to show success with our V-chip licensing to internationally-based television manufacturers. This relationship with Pheromone and Boots is a clear demonstration of Tri-Vision Technologies ability to market internationally." stated Tri-Vision Technologies President Toshginori Ikebe.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and do not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News